However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...

There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...

On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...

Shares of Eli Lilly & Co. LLY advanced 2.48% to $733.29 Thursday, on what proved to be an all-around great trading session ...

Shares of pharmaceutical companies dropped early Monday after President Donald Trump said he would lower the cost of ...

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...

Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...

President Donald Trump's second term in office has been challenging for investors, at least so far. Trump imposed sweeping ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...